Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2022 November 18, 2022
Intensity Therapeutics’ INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers November 11, 2022
Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers November 10, 2022
Intensity Therapeutics’ Data on Lead Asset, INT230-6, Accepted for Three Presentations at Key Upcoming Clinical Oncology Conferences in November November 1, 2022
Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers June 6, 2022
Intensity Therapeutics’ INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers June 3, 2022
Intensity Therapeutics’ INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas June 2, 2022
Intensity Therapeutics Announces New Clinical Data in Solid Tumors for its Lead Asset, INT230-6, Were Accepted for Two Poster Discussion Sessions and Three Poster Presentations at the Upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting May 3, 2022
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium® December 10, 2021
Intensity Therapeutics Announces New Clinical Data Presentation for its Lead Asset, INT230-6, in Breast Cancer, at the 2021 San Antonio Breast Cancer Symposium® in December November 30, 2021
Intensity Therapeutics Reports Promising Overall Survival Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab or Ipilimumab to Treat Solid Tumors, at The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting November 13, 2021
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting November 12, 2021
Intensity Therapeutics’ Data on Lead Asset, INT230-6, Accepted for Presentation at Two Major Scientific Clinical Oncology Conferences in November November 3, 2021
Murphy Highlights Westport Innovator Intensity Therapeutics as “Innovator of the Month” June 30, 2021
Intensity Therapeutics’ INT230-6 Demonstrates Efficacy as Either Monotherapy or in Combination with Checkpoint Inhibitors in Patients with Relapsed, Refractory, Metastatic Solid Tumors June 2, 2021
Intensity Therapeutics Announces Two Abstracts to Be Presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting May 20, 2021
Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Sign Agreements to Conduct a Phase 2 Randomized, Window of Opportunity Trial in Early-Stage Breast Cancer March 24, 2021
Intensity Therapeutics Reports Favorable Data of INT230-6 from the Ongoing Phase 1/2 Study (IT-01/KEYNOTE A10) in Patients with Advanced Solid Tumors at SITC 2020 (Abstract 411) November 11, 2020
Intensity Therapeutics Doses First Patient with Combination of INT230-6 and Bristol Myers Squibb’s Yervoy® in a Phase 2 Study September 17, 2020
